Clinical Application of Real-World Evidence for Stroke Prevention in Atrial Fibrillation and the Treatment of Venous Thromboembolism (CARE-AF/VTE Program)
Multi-channel, Multi-National Learning Series for Clinicians
CE Credit Available
AC FORUM
Description
Despite the considerable efficacy of oral anticoagulants for the prevention of stroke in atrial fibrillation and the treatment of acute venous thromboembolism, published analyses of real-world evidence suggest that a significant proportion of patients eligible for DOACs for these conditions either do not receive guideline-recommended therapy or they receive dosages that are not in alignment with package labeling or consensus guidelines, resulting in suboptimal patient outcomes.
Gaps in clinician knowledge result in suboptimal patient outcomes due to under-use of anticoagulant therapy, inappropriate dosing, and poor clinical decision-making among patients in high-risk populations.
Timeline:
Each of the Atrial Fibrillation and Venous Thromboembolism units will consist of four weekly lessons, with a total of eight weeks for the full course. Presentations will be brief (30 minutes) to accommodate clinician availability.
You have the choice to register for one pathway or for both. Registration closes on January 3, 2025.
Target Audience:
The CARE-AF/VTE Program is designed to meet the educational needs of practicing clinicians in European countries who are most likely to encounter and manage patients with AF and VTE, including general medicine, cardiology, hematology, emergency medicine, vascular medicine, and others.
Accreditation Continuing Education
The individual AF and VTE units are accredited for up to 2.5 hours of continuing education credits for physicians, nurses, and pharmacists. The full 8-week program is eligible for up to 5.0 hours.
Clinical Application of Real-World Evidence for the Treatment of Atrial Fibrillation
Faculty: Gregory Y. H. Lip, MD, FRCP (London Edinburgh Glasgow), DFM, AFHEA, FACC, FESC, FEHRA, iFAPHRS
Session 1: Direct Oral Anticoagulant Use in Atrial Fibrillation
Session 2: Direct Oral Anticoagulant Use in Special Populations with Atrial Fibrillation
Session 3: Anticoagulation Stewardship of Direct Oral Anticoagulant Therapy in Atrial Fibrillation
Session 4: Atrial Fibrillation – Q&A with Experts
Faculty: Gregory Y. H. Lip, MD; Walter Ageno, MD; Edelgard Lindhoff-Last, MD; Karina Meijer, MD, PhD; Gheorghe Dan, MD; and Mark Crowther, MD, MSc (moderator)
Clinical Application of Real-World Evidence for the Treatment of Venous Thromboembolism
Faculty: Walter Ageno, MD
Session 1: Direct Oral Anticoagulant Use in Venous Thromboembolism
Session 2: Direct Oral Anticoagulant Use in Special Populations with Venous Thromboembolism
Session 3: Anticoagulation Stewardship of Direct Oral Anticoagulant Therapy in Venous Thromboembolism
Session 4: Venous Thromboembolism – Q&A with Experts
Faculty: Walter Ageno, MD; Edelgard Lindhoff-Last, MD; Karina Meijer, MD, PhD; Antoni Martínez-Rubio, MD; and Scott Kaatz, DO, MSc (moderator)
The Anticoagulation Forum is honored to receive the endorsement of the International Society of Cardiovascular Pharmacotherapy (ISCP) for our Clinical Application of Real-World Evidence for Stroke Prevention in Atrial Fibrillation and the Treatment of Venous Thromboembolism (CARE-AF/VTE) Program. This recognition reinforces the importance of our mission to close the gaps in clinician knowledge that lead to suboptimal patient outcomes in the use of direct oral anticoagulants (DOACs).
The endorsement by ISCP—an organization dedicated to improving cardiovascular health through interdisciplinary collaboration and the promotion of evidence-based clinical management—underscores the value of the CARE-AF/VTE Program. Together, AC Forum and ISCP are committed to equipping healthcare professionals with the latest insights and best practices to improve the prevention of stroke in atrial fibrillation and the treatment of venous thromboembolism, advancing our shared goal of enhancing patient outcomes around the world.
